Izotropic is a medical technology company pioneering the commercialization of IzoView, the world’s first dedicated 3D Breast CT imaging system designed to transform how breast cancer is detected, diagnosed, and monitored. Built on more than a decade of clinical research and development at the University of California, Davis, IzoView delivers true volumetric imaging in seconds—without compression, pain, or discomfort—offering sub-millimeter resolution and earlier detection capabilities than existing modalities. Izotropic’s mission is to establish a new global standard of care for breast imaging by providing a faster, more accurate, and more patient-friendly solution. As the company advances toward FDA pivotal trials and commercialization, Izotropic is strategically positioned to capture a significant share of the multi-billion-dollar breast imaging market through hospital installations, mobile diagnostic units, and AI-integrated imaging solutions that improve outcomes for women worldwide.
